Seminars in Cutaneous Medicine and Surgery Seminars in Cutaneous Medicine and Surgery RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Targeted therapies for pediatric psoriasis.
Authors: Schwartz G, Paller AS Abstract Children who are recalcitrant to topical therapy for their moderate to severe plaque psoriasis and/or highly visible lesions may be candidates for systemic therapy. Methotrexate has been the most commonly used systemic agent in children. However, at least 25% of patients are now treated with biologics, especially tumor necrosis factor-α inhibitors, and their use is expanding as their availability, demonstrated safety and efficacy, and practitioner experience are increasing. In the United States, etanercept is Food and Drug Administration approved for ages 6 years an...
Source: Seminars in Cutaneous Medicine and Surgery - September 16, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Targeted therapies for psoriatic arthritis: an update for the dermatologist.
Authors: Elman SA, Weinblatt M, Merola JF Abstract Dermatologists are on the front line to identify psoriatic arthritis (PsA) in their patients with psoriasis. PsA is a prevalent and underdiagnosed disease with potential long-term complications and sequelae for patients. Targeted biologics have transformed the landscape of psoriasis and PsA therapy. These medications variably treat clinical manifestations of psoriatic disease: skin psoriasis, peripheral and axial arthritis, enthesitis, and nail disease. With many new medications either on the market or currently being evaluated by the Food and Drug Adminis...
Source: Seminars in Cutaneous Medicine and Surgery - September 16, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
Authors: Porter ML, Golbari NM, Lockwood SJ, Kimball AB Abstract Hidradenitis suppurativa (HS) is a frequently devastating inflammatory skin disorder. Although many treatments have been tried and tested to date, there is only one Food and Drug Administration-approved treatment option, adalimumab, which is currently indicated for moderateto- severe HS. Our understanding of the management of HS with biologic agents and with nonantibiotic and/ or antimicrobial systemic therapies continues to evolve. In this article, we summarize the existing data on biologics and other small-molecule systemic agents, as well ...
Source: Seminars in Cutaneous Medicine and Surgery - September 16, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Novel therapies in the treatment of atopic dermatitis.
Authors: Zhong CS, Elmariah SB Abstract Atopic dermatitis (AD) is a common cutaneous condition characterized by epidermal barrier disruption, severe skin inflammation, and pruritus. As a result of our growing understanding of disease pathogenesis, the therapeutic armamentarium to manage AD is rapidly expanding. Moving beyond broadly immunosuppressive agents, newer therapies for AD offer more targeted immunomodulation in the forms of phosphodiesterase 4 inhibitors, Janus kinase inhibitors, and anticytokine monoclonal antibodies. While such therapies are generally considered safer than traditional immunosupp...
Source: Seminars in Cutaneous Medicine and Surgery - September 16, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Authors: Khan J, Deverapalli SC, Rosmarin D Abstract Cutaneous inflammatory conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo, and connective tissue diseases often remain a challenge to treat. Although there is an in-depth understanding of the clinical presentation of these diseases, much less is known regarding the pathophysiology. This has limited the effective treatment options for patients. A more detailed understanding of the pathogenesis of each disease will lead to newer targeted medications with less morbidity. Though there are different pathways involved in these diseases,...
Source: Seminars in Cutaneous Medicine and Surgery - September 16, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Introduction.
Authors: Stein Gold LF PMID: 30192342 [PubMed - in process] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - September 9, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Current Concepts in Acne Pathogenesis: Pathways to Inflammation.
Authors: Tan JKL, Stein Gold LF, Alexis AF, Harper JC Abstract Acne is a disease of pilosebaceous inflammation. Pivotal in pathogenesis are the roles of hormones (insulin, insulin-like growth factor-1, androgens), Propionibacterium acnes, lipogenesis, and a proinflammatory lipid profile. Innate immune responses are induced through interaction with toll-like receptors and inflammasome activation initially and subsequently through adaptive immune activation. These insights into pathogenic inflammatory pathways can translate into novel therapeutic approaches for acne. Semin Cutan Med Surg 37(supp3):S60-S62 ©...
Source: Seminars in Cutaneous Medicine and Surgery - September 9, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Advances in Acne and Rosacea Therapy.
Authors: Stein Gold LF, Alexis AF, Harper JC, Tan JKL Abstract New topical therapies have demonstrated efficacy in patients with moderate or severe acne who might otherwise have required therapy with systemic antibiotics or isotretinoin. Increasing knowledge about the pathogenesis of acne has facilitated the development of therapies with novel modes of action. New and investigational therapies also are available or in development for the treatment of both the papulopustular and erythematous manifestations of rosacea. Semin Cutan Med Surg 37(supp3):S63-S66 © 2018 published by Frontline Medical Communicatio...
Source: Seminars in Cutaneous Medicine and Surgery - September 9, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Treating Acne in Adult Women.
Authors: Harper JC, Stein Gold LF, Alexis AF, Tan JKL Abstract Acne can persist into adulthood or erupt de novo at any point after adolescence. Adult acne is more common in women than in men. Considerations for treating acne in adult women include childbearing potential, pregnancy, lactation, and concomitant skin conditions. Semin Cutan Med Surg 37(supp3):S67-S70 © 2018 published by Frontline Medical Communications. PMID: 30192345 [PubMed - in process] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - September 9, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Treating Acne in Patients With Skin of Color.
Authors: Alexis AF, Harper JC, Stein Gold LF, Tan JKL Abstract Patients with skin of color are more likely to develop acne and postinflammatory hyperpigmentation (PIH). Many therapies for acne have demonstrated efficacy in darker skin types and in the treatment of PIH. Semin Cutan Med Surg 37(supp3):S71-S73 © 2018 published by Frontline Medical Communications. PMID: 30192346 [PubMed - in process] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - September 9, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Melanocytic Neoplasms, Introduction.
Authors: Daud AI PMID: 30040084 [PubMed - in process] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - July 25, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Pathologic analysis of melanocytic neoplasms.
Authors: Messina JL, Gibbs J Abstract Recent advances in techniques for pathologic evaluation of melanocytic neoplasms, updates in staging, and novel treatment and prognostic assays have brought pathologists to the forefront of the care of the melanoma patient. Specimen procurement, handling, and evaluation are all key to the production of a pathology report that guides the clinician to the proper treatment of the patient. Recent, relevant changes in the pathologic analysis of melanocytic neoplasms, highlighting the AJCC 8th edition guidelines, and pathologic changes related to therapy are discussed herein...
Source: Seminars in Cutaneous Medicine and Surgery - July 25, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Surgical management of melanoma.
Authors: Burke EE, Sondak VK Abstract Surgery remains one of the key treatment modalities for melanoma. Wide excision of the primary site with sentinel lymph node biopsy for selected patients has been recognized as the standard surgical approach for patients with early-stage disease. Controversies persist regarding margin width, indications for sentinel lymph node biopsy, and surgical management of regional nodal basins. Additionally, new therapies such as intralesional therapies as well as new systemic therapies are changing the role for surgery in patients with recurrent local-regional as well as metasta...
Source: Seminars in Cutaneous Medicine and Surgery - July 25, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

Adjuvant therapy for resected high-risk melanoma.
Authors: Moser JC, Grossman KF Abstract Melanoma is an aggressive cancer that arises from melanocytes that can both locally invade surrounding tissues as well as metastasize systemically. If detected early, melanoma can be curable with surgical resection. However, despite complete removal, high-risk resected melanomas have a significant rate of both local and distant recurrence. Curative treatment options are typically limited for patients who develop distant recurrence after resections of their primary melanoma. Therefore, adjuvant therapy is typically given after complete resection of high-risk melanomas...
Source: Seminars in Cutaneous Medicine and Surgery - July 25, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

The role of targeted therapy for melanoma in the immunotherapy era.
Authors: Sullivan RJ Abstract Over the past 10 years of remarkable development of both molecularly targeted and immune-targeted therapy for the treatment of melanoma, a clear preference of immunotherapy over molecularly targeted therapy has emerged among melanoma treatment providers. Still, the clinical data remain remarkable for patients with BRAF-mutant stage III and IV melanoma, and there seems to be a clear benefit of BRAF-targeted therapy for these patients. The key, then, is to identify the best way to use BRAF-targeted therapy. In this review, the clinical data of molecular-targeted therapy are summ...
Source: Seminars in Cutaneous Medicine and Surgery - July 25, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research